Literature DB >> 6143660

The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes.

B D Koch, A Schonbrunn.   

Abstract

Somatostatin (SRIF) inhibits vasoactive intestinal peptide (VIP)-stimulated cAMP accumulation in the GH4C1 strain of rat pituitary tumor cells, and this effect is responsible for SRIF inhibition of VIP-stimulated hormone release. In this study we examined the interaction between the SRIF receptor and adenylate cyclase in GH4C1 cell membranes. Maximal concentrations of VIP (50 nM) increased membrane adenylate cyclase activity 4.2-fold; half-maximal stimulation was observed with 0.75 nM VIP. SRIF noncompetitively inhibited the stimulatory effect of VIP, but it did not alter basal adenylate cyclase activity. The relative potencies of SRIF and two SRIF analogs as inhibitors of VIP-stimulated adenylate cyclase activity in membranes and of VIP-stimulated cAMP accumulation in intact cells were similar. Furthermore, the concentration of SRIF that caused half-maximal inhibition of adenylate cyclase activity (ED50 = 2.3 nM) was close to the equilibrium dissociation constant for SRIF (Kd = 0.40 nM) measured in membrane preparations in the presence of GTP. Therefore, SRIF inhibition of adenylate cyclase appears to be receptor mediated. As with receptors known to regulate adenylate cyclase by interaction with a guanine nucleotide regulatory subunit, SRIF receptor binding was decreased in the presence of guanine nucleotides. Addition of GTP (150 microM) or the nonhydrolyzable GTP analog guanyl-5'-yl-imidodiphosphate (100 microM) decreased the specific binding of [125I-Tyr1]SRIF to 31% and 13% of the control value, respectively. This decrease in specific binding was due entirely to decreased receptor affinity for SRIF. GTP (150 microM) increased the equilibrium dissociation constant for SRIF from 0.11 to 0.40 nM, whereas the number of binding sites was unaffected by the nucleotide (Bmax = 0.2 pmol/mg protein). Analysis of dissociation kinetics demonstrated that in the absence of guanyl nucleotides, the rate of [125I-Tyr1]SRIF dissociation was first order (t 1/2 = 180 min). However, in the presence of a half-maximal concentration of guanyl-5'-yl-imidodiphosphate (0.3 microM), [125I-Tyr1]SRIF dissociation occurred with biphasic kinetics. Fifty percent of the specifically bound peptide dissociated at the same rate as that observed in the absence of nucleotide, whereas the remainder dissociated 15 times more rapidly (t 1/2 = 9.6 min).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143660     DOI: 10.1210/endo-114-5-1784

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

1.  Somatostatin receptors on human lymphocytes and leukaemia cells.

Authors:  K Hiruma; T Koike; H Nakamura; T Sumida; T Maeda; H Tomioka; S Yoshida; T Fujita
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

2.  Localization of the somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody.

Authors:  P Dournaud; Y Z Gu; A Schonbrunn; J Mazella; G S Tannenbaum; A Beaudet
Journal:  J Neurosci       Date:  1996-07-15       Impact factor: 6.167

3.  Somatostatin receptors and the effect of somatostatin on histamine-stimulated adenylate cyclase activity in isolated gastric glands of guinea pigs.

Authors:  K Yoshida; S Nishihara; T Misawa; H Nawata
Journal:  Gastroenterol Jpn       Date:  1989-12

4.  Purification of a putative brain somatostatin receptor.

Authors:  H T He; K Johnson; K Thermos; T Reisine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  Molecular characterization of the solubilized receptor of somatostatin from rat pancreatic acinar membranes.

Authors:  S Knuhtsen; J P Esteve; B Bernadet; N Vaysse; C Susini
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

Review 6.  Somatostatin.

Authors:  S R Bloom; J M Polak
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-01

7.  Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Larry Kvols
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

Review 8.  Molecular pharmacology of somatostatin receptors.

Authors:  D Hoyer; H Lübbert; C Bruns
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

9.  Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue.

Authors:  A E Siperstein; K E Levin; E T Gum; O H Clark
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

10.  Immunocytochemical study of the GH cells in the anterior pituitary gland of human fetus II. Anencephalic fetus.

Authors:  Toshiaki Tachibana; Takayasu Ito
Journal:  Hum Cell       Date:  2003-12       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.